Obesity In India

Beyond labels: What India needs to do to limit ultra-processed foods

India still has a critical advantage: ultra-processed foods account for a very small share of current diets

Eli Lilly, Novo Nordisk compete for lead in India's obesity drug market

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

Why does belly fat rise after 30 even when diet and workouts stay same?

Why does belly fat creep up after 30 even if nothing has changed? A California-based gastroenterologist trained at AIIMS explains the science behind it and what can help reverse it

GLP-1 weight-loss drugs likely to see value growth slowing down

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

Ozempic in India: What it does and how it fits into a growing health crisis

From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions

Eli Lilly's Mounjaro tops India pharma charts with ₹100 crore sales in Oct

Mounjaro is part of a new generation of weight-loss and diabetes drugs that target metabolic hormones. Introduced in March, it was launched ahead of rival Novo Nordisk's Wegovy

India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

After Mounjaro success, Eli Lilly plans to launch weight-loss pill in India

Unlike injectable Mounjaro, which focuses on patients with a BMI above 35, Orforglipron is designed for the larger group of patients with a BMI of 27-34, offering an expected weight reduction of 12-16

FSSAI to ask restaurants to display sugar, oil info to curb obesity

The development comes in line with growing obesity numbers in India, with a recent Lancet study projecting over 440 million obese and overweight people by 2050

Anti-obesity drug war heats up as Wegovy and Mounjaro boost sales

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising obesity and growing doctor awareness

Can Mounjaro transform obesity care? ₹50 crore sales in three months

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three months

Can lemon water burn fat? Experts bust 15 weight loss myths you believe

From lemon water and detox drinks to skipping rice and sweating more, experts separate fat-loss facts from fiction to help you focus on what works

Anti-obesity mkt heats up as Mounjaro's Kwikpen version gets India approval

With CDSCO approval, Mounjaro to be available in a Kwikpen format; this comes a day after Wegovy's India launch, intensifying competition in weight-loss treatment

Novo Nordisk launches Wegovy in India to tackle obesity and heart risk

Wegovy is India's first weekly injectable approved for both long-term weight loss and reducing heart risks in obese and overweight adults

India's response to obesity drug Mounjaro 'positive', says Eli Lilly

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May

Delhi schoolkids face surge in obesity and hypertension, warns Aiims study

A new Aiims study reveals a worrying rise in obesity, hypertension and hidden metabolic risks among Delhi schoolchildren, especially those in private schools

Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

India's oil intake has tripled-how much is too much for your health?

India's per capita oil intake has jumped to 23.5 kg a year-nearly twice the ICMR's limit-raising health concerns over obesity, heart disease, and diabetes

Why Mounjaro's India entry has doctors and patients picking up the phone

With obesity on the rise, Eli Lilly's weight-loss injection triggers a rush of consultations as Indians seek safer, cheaper options to black-market drugs

Obesity cure is here? Why it could be a win-win for all stakeholders

We Indians have had a different perspective around obesity